Cerevel Therapeutics Holdings Inc (CERE)

Cerevel Therapeutics Holdings Inc Borsa (CERE) Ultime notizie

INVESTIGATION ANNOUNCEMENT: BFA Law Announces an Ongoing Investigation into the Merger between Cerevel Therapeutics and AbbVie for Unfair Process - ForexTV.com

ForexTV.com

INVESTIGATION ANNOUNCEMENT: BFA Law Announces an Ongoing Investigation into the Merger between Cerevel ... - GlobeNewswire

GlobeNewswire

Market Recap Check: Cerevel Therapeutics Holdings Inc (CERE)'s Positive Finish at 42.31, Up/Down 0.17 – DWinneX - The Dwinnex

The Dwinnex

Recent Insider Activity Could Benefit Cerevel Therapeutics Holdings Inc (CERE) – Knox Daily - Knox Daily

Knox Daily

Insider Selling: Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) Director Sells 50,000 Shares of Stock - MarketBeat

MarketBeat

Insider Selling: Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) Director Sells 50,000 Shares of Stock - MarketBeat

MarketBeat

AbbVie (ABBV) Boosts Neuropsychiatric Portfolio With New Deal

Zacks Investment Research

CEREVEL THERAPEUTICS HOLDINGS, INC. (NASDAQ: CERE) INVESTIGATION ALERT: Is $45 per CERE Share ... - GlobeNewswire

GlobeNewswire

Versor Investments LP Invests $4.61 Million in Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) - MarketBeat

MarketBeat

20,300 Shares in Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) Bought by Kellner Capital LLC - MarketBeat

MarketBeat

Segantii Capital Management Ltd Acquires Shares of 594,519 Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) - MarketBeat

MarketBeat

One Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) insider upped their stake by 148% in the previous year - Yahoo Lifestyle UK

Yahoo Lifestyle UK

Exclusive-AbbVie nears roughly $8 billion deal for drug developer Cerevel-sources - Yahoo Movies Canada

Yahoo Movies Canada

International Assets Investment Management LLC Invests $23.37 Million in Cerevel Therapeutics Holdings, Inc ... - MarketBeat

MarketBeat

Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) Given Average Rating of "Hold" by Analysts - MarketBeat

MarketBeat

CERE's Stock Market Pendulum: Swinging Between Gains and Losses – Invest Chronicle - The InvestChronicle

The InvestChronicle

CEREVEL SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Cerevel Therapeutics Holdings, Inc ... - GlobeNewswire

GlobeNewswire

CEREVEL SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Cerevel Therapeutics Holdings, Inc ... - GlobeNewswire

GlobeNewswire

Cerevel's Parkinson's success is music to AbbVie's ears - The Pharma Letter

The Pharma Letter

A company insider recently sold 50000 shares of Cerevel Therapeutics Holdings Inc [CERE]. Should You Sale? – Knox ... - Knox Daily

Knox Daily

Parkinson's Results Further Sweeten AbbVie's Acquisition of Cerevel - Scrip

Scrip

Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson’s Disease

GlobeNewswire Inc.

Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living ... - GlobeNewswire

GlobeNewswire

Neumora Tumbles as Early-Stage Study Put on Clinical Hold - Bloomberg

Bloomberg

Neurosterix emerges with $63m for neuroscience pipeline - pharmaphorum

pharmaphorum

AbbVie (ABBV) to Buy Landos to Strengthen Autoimmune Portfolio

Zacks Investment Research

Strike While The Market Is Hot

Seeking Alpha

30 Biggest Biotechnology Companies in the World - Insider Monkey

Insider Monkey

Cerevel Therapeutics: Parkinson's Could Be The Issue (NASDAQ:CERE) - Seeking Alpha

Seeking Alpha

Minerva setback doesn't preclude big year for schizophrenia - BioCentury

BioCentury

Is AbbVie Stock a Buy Now?

The Motley Fool

AbbVie Eyes $13 Billion Bond Sale to Finance Acquisitions: A Deep Dive into the Strategic Move - Medriva

Medriva

AbbVie (ABBV) Announces Appointment of New CEO Robert Michael

Zacks Investment Research

AbbVie Eyes Selling at Least $13 Billion of Bonds to Fund M&A - Bloomberg

Bloomberg

AbbVie taps new CEO as it faces fresh competition for blockbuster drug Humira

MarketWatch

AbbVie's Cerevel deal hits an uncommon roadblock - Yahoo Finance

Yahoo Finance

Cerevel Therapeutics Advances in Merger Amid FTC Review - TipRanks.com - TipRanks

TipRanks

This Analyst Is Bullish On Biohaven's Approach in Neuro-Psych Space

Benzinga

Cerevel, AbbVie get FTC Second Requests for more merger info (NASDAQ:CERE) - Seeking Alpha

Seeking Alpha

AbbVie lowers first-quarter guidance after closing acquisition ImmunoGen

MarketWatch

AbbVie Cuts Its Guidance on ImmunoGen Deal - Investopedia

Investopedia

UBS Bullish On This Depression Drug Maker, Says Alzheimer's Agitation Data Is Attractive Catalyst

Benzinga

AbbVie’s fourth-quarter sales top estimates despite plunging Humira revenues

MarketWatch

AbbVie's Transformational 2023, Analyst Anticipates Growth in 2024 Amid Competitive Pressures

Benzinga

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: McGrath RentCorp ... - GlobeNewswire

GlobeNewswire

Schizophrenia pipeline: two PDUFA dates and a dozen readouts in 2024 - BioCentury

BioCentury

Karuna, Cerevel might be just the start of psychiatry drug M&A - Yahoo Finance

Yahoo Finance

Is AbbVie Stock a Buy Now?

The Motley Fool

JP Morgan Maintains Neutral Rating for Cerevel Therapeutics Hldg: Here's What You Need To Know

Benzinga

Karuna (KRTX) Up 48% on $14B Buyout Offer From Bristol Myers

Zacks Investment Research